Brief: XSpray Pharma Changes Timeline For Dasynoc FDA Application Sumbission
Jan 8 (Reuters) - XSpray Pharma AB (publ) XSPRAY.ST :
* CHANGES TIMELINE FOR SUMBISSION OF APPLICATION TO FDA FOR
DASYNOC
* EXPECTS TO SUBMIT UPDATED APPLICATION IN MARCH/APRIL 2025
Source text: ID:nMFN1DLssM
Further company coverage: XSPRAY.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Xspray Pharma publ AB
See all newsBrief: Xspray Pharma Gets CRL From FDA
Sweden's Xspray Q1 loss narrows, upbeat on Dasynoc prospects
Brief: Xspray Pharma Q1 Pretax Loss SEK 35.4 Mln
Brief: Xspray Pharma To Receive About SEK 113 Million From Rights, Over-Allotment Issues
Brief: FDA Accepts Trade Name Nilopki For Xspray's Drug Candidate XS003